<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv=Content-Type content="text/html; charset=iso-8859-1">
<meta name=Generator content="Microsoft Word 12 (filtered medium)">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<style>
<!--
/* Font Definitions */
@font-face
        {font-family:Calibri;
        panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
        {font-family:Tahoma;
        panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
        {margin:0cm;
        margin-bottom:.0001pt;
        font-size:12.0pt;
        font-family:"Times New Roman","serif";}
a:link, span.MsoHyperlink
        {mso-style-priority:99;
        color:blue;
        text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
        {mso-style-priority:99;
        color:purple;
        text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
        {mso-style-priority:99;
        mso-style-link:"Balloon Text Char";
        margin:0cm;
        margin-bottom:.0001pt;
        font-size:8.0pt;
        font-family:"Tahoma","sans-serif";}
span.EmailStyle17
        {mso-style-type:personal-compose;
        font-family:"Calibri","sans-serif";
        color:windowtext;}
span.BalloonTextChar
        {mso-style-name:"Balloon Text Char";
        mso-style-priority:99;
        mso-style-link:"Balloon Text";
        font-family:"Tahoma","sans-serif";}
.MsoChpDefault
        {mso-style-type:export-only;}
@page WordSection1
        {size:612.0pt 792.0pt;
        margin:70.85pt 70.85pt 70.85pt 70.85pt;}
div.WordSection1
        {page:WordSection1;}
-->
</style>
<!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="2050" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang=IS link=blue vlink=purple>
<div class=WordSection1>
<p class=MsoNormal><b><img width=604 height=70 id="_x0000_i1025"
src="cid:image001.jpg@01CB0BA6.8872E960"></b><b><o:p></o:p></b></p>
<p class=MsoNormal><span style='font-size:10.0pt;color:#217521'>Þessi póstur er
sendur tengiliðum við stofnanir, fyrirtæki, félög og hópa, til að kynna
fræðsluerindi sem haldin eru á Tilraunastöðinni að Keldum. Vinsamlegast
áframsendið með tölvupósti eftirfarandi upplýsingar til ykkar fólks.<o:p></o:p></span></p>
<p class=MsoNormal><b><span style='color:red'><o:p> </o:p></span></b></p>
<p class=MsoNormal><b>Fræðsluerindi á vegum Tilraunastöðvar Háskóla Íslands í
meinafræði að Keldum.<o:p></o:p></b></p>
<p class=MsoNormal><o:p> </o:p></p>
<p class=MsoNormal>Fyrirlesari: <b>Gustav Ranheimer Östner</b> doktorsnemi við
læknadeild Háskólans í Lundi.<o:p></o:p></p>
<p class=MsoNormal style='text-autospace:none'>Heiti erindis: <b><span
lang=EN-GB>Molecular Pathology of Hereditary Cerebral Hemorrhage in Iceland
(arfgeng heilablæðing)</span></b><span lang=EN-GB>.<o:p></o:p></span></p>
<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB><o:p> </o:p></span></p>
<p class=MsoNormal>Erindið verður haldið <u>miðvikudaginn 16. júní, kl. 12:20</u>
á Tilraunastöð Háskóla Íslands í meinafræði að Keldum.<o:p></o:p></p>
<p class=MsoNormal style='mso-margin-top-alt:auto;mso-margin-bottom-alt:auto'><span
lang=EN-GB>A number of Icelandic families are affected by Hereditary Cystatin C
Amyloid Angiopathy (arfgeng heilablæðing). In this human disease, L68Q variant
cystatin C deposits as amyloid within cerebral vessels, causing dementia and
death from cerebral hemorrhage, in early adult life. The protein cystatin C, a
cysteine protease inhibitor, has been shown to dimerize via three-dimensional
domain swapping, and the same mechanism has been associated with formation of
oligomers and amyloid fibrils. In this presentation, our current knowledge of
the molecular mechanisms in this disease, will be reviewed. Recent efforts in
finding novel treatments, will be highlighted.<o:p></o:p></span></p>
<p class=MsoNormal>______________________________________________________________<o:p></o:p></p>
<p class=MsoNormal><span style='font-size:10.0pt'><o:p> </o:p></span></p>
<p class=MsoNormal><span style='font-size:9.0pt'>Sigurður H. Richter<o:p></o:p></span></p>
<p class=MsoNormal><span style='font-size:9.0pt'>Tilraunastöð H.Í. í meinafræði
að Keldum<o:p></o:p></span></p>
<p class=MsoNormal><span style='font-size:9.0pt'>Símar 585 5100 og 896 5811<o:p></o:p></span></p>
<p class=MsoNormal><span style='font-size:9.0pt'>Tölvupóstfang <a
href="mailto:shr@hi.is" title="mailto:shr@hi.is">shr@hi.is</a><o:p></o:p></span></p>
<p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri","sans-serif"'><o:p> </o:p></span></p>
</div>
</body>
</html>